Share This Page
Suppliers and packagers for generic pharmaceutical drug: leuprolide mesylate
✉ Email this page to a colleague
leuprolide mesylate
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Accord | CAMCEVI KIT | leuprolide mesylate | EMULSION;SUBCUTANEOUS | 211488 | NDA | Accord BioPharma, Inc. | 69448-014-63 | 1 SYRINGE in 1 CARTON (69448-014-63) / .37 g in 1 SYRINGE | 2022-04-05 |
| Accord | CAMCEVI KIT | leuprolide mesylate | EMULSION;SUBCUTANEOUS | 211488 | NDA | Accord BioPharma, Inc. | 69448-023-63 | 1 SYRINGE in 1 CARTON (69448-023-63) / .37 g in 1 SYRINGE | 2025-05-19 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Leuprolide Mesylate
Introduction
Leuprolide Mesylate is a synthetic gonadotropin-releasing hormone (GnRH) analog widely used in hormone-dependent cancers such as prostate cancer, and in conditions like endometriosis and precocious puberty. Its pivotal role in hormone therapy and reproductive health underscores the importance of a reliable supply chain. This article provides a detailed overview of key suppliers, manufacturing capacity, market dynamics, and strategic considerations associated with sourcing Leuprolide Mesylate, essential for pharmaceutical companies, wholesalers, and healthcare providers.
Overview of Leuprolide Mesylate
Leuprolide Mesylate functions as a potent GnRH agonist that initially stimulates, then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased testosterone and estrogen production. It is principally administered via injections, with formulations such as Lupron and supply on the global pharmaceutical market primarily regulated, manufactured, and distributed by a select group of leading pharmaceutical firms.
Major Suppliers and Manufacturers
1. Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global leader in reproductive medicine and hormone therapies, including Leuprolide Mesylate. They manufacture and market Lupron Depot, which contains leuprolide acetate, a close analog often used interchangeably in clinical and pharmaceutical contexts. Ferring's manufacturing facilities are compliant with current Good Manufacturing Practices (cGMP), ensuring high-quality standards [1]. Their extensive distribution network covers North America, Europe, and parts of Asia.
2. AbbVie
AbbVie (formerly part of Abbott Laboratories) produces Lupron, a branded leuprolide acetate formulation. Their manufacturing capacity encompasses both vials and depot formulations, catering to diverse clinical needs. With robust R&D capabilities and a strategic focus on oncology and gynecology indications, AbbVie's supply chain stability makes it a significant supplier globally [2].
3. Sun Pharmaceutical Industries
One of India's largest generic pharmaceutical companies, Sun Pharma, manufactures and supplies Leuprolide Mesylate through various formulations. They focus on generic versions, offering cost-effective options with wide market reach, especially in emerging markets. Their manufacturing compliance with international standards ensures quality and regulatory approval in multiple regions [3].
4. Takeda Pharmaceuticals
Takeda, a Japanese multinational, offers proprietary formulations of Leuprolide for various indications, particularly in Asia and Europe. Their established infrastructure supports large-scale production and distribution, ensuring consistent supply channels globally.
5. Other Notable Manufacturers
- Ipsen: Known for their collaboration with pharmaceutical distribution entities to supply Leuprolide formulations primarily in the European market.
- Sandoz (Novartis): Supplies generic Leuprolide implementations with competitive pricing strategies.
Manufacturing Capacities and Distribution Dynamics
The manufacturing capacity for Leuprolide Mesylate has expanded over recent years owing to increased demand driven by cancer treatment protocols and reproductive health needs. Ferring and AbbVie dominate the market share, with production facilities located in North America, Europe, and Asia facilitating regional demands.
The complexity of peptide synthesis, stability considerations, and quality control significantly influence manufacturing scalability and lead times. Additionally, regulatory approvals and patent protections impact market entry, especially for generic manufacturers aiming to compete with branded formulations.
Market Trends and Sourcing Considerations
-
Patents and Exclusivity: Patent expirations in several jurisdictions have opened avenues for generic manufacturers, diversifying supply sources.
-
Regulatory Compliance: Ensure suppliers comply with cGMP, ISO standards, and have robust quality assurance to mitigate risks of substandard products.
-
Cost Dynamics: Generic suppliers typically offer lower prices, vital for budget-sensitive healthcare systems, but must align quality standards.
-
Supply Chain Resilience: Recent global disruptions have emphasized the importance of diversification in supplier portfolios to prevent shortages.
Emerging Suppliers and Market Opportunities
The growing demand for Leuprolide Mesylate, particularly in emerging markets, has prompted new entrants in the manufacturing landscape. Companies investing in peptide synthesis technology and API (Active Pharmaceutical Ingredient) production capabilities can capitalize on the increasing global need. Moreover, digital transformation in supply chain management allows for enhanced procurement strategies and real-time inventory tracking.
Key Challenges and Strategic Risks
- Supply Disruptions: Monopolistic manufacturing or supply chain bottlenecks can lead to shortages.
- Quality Assurance Risks: Verifying the authenticity and quality of supplies, especially from emerging markets, remains critical.
- Price Competition: Intense market competition can pressure margins, necessitating strategic sourcing partnerships.
Conclusion
Securing reliable suppliers of Leuprolide Mesylate necessitates a comprehensive understanding of market players, manufacturing capacities, regulatory landscapes, and geopolitical factors influencing supply chains. Industry leaders like Ferring Pharmaceuticals and AbbVie dominate the market due to their extensive manufacturing infrastructure, quality assurance, and global distribution networks. Meanwhile, the rise of generics, led by companies such as Sun Pharma, offers more accessible options but requires diligence in quality and regulatory compliance.
In a market characterized by evolving patent landscapes and manufacturing innovations, diversified sourcing strategies ensure supply continuity, cost efficiency, and quality assurance—pivotal for the sustained success of healthcare providers and pharmaceutical distributors.
Key Takeaways
- Market Leaders: Ferring Pharmaceuticals and AbbVie are primary suppliers, with robust manufacturing and distribution infrastructure.
- Generic Growth: Indian and other emerging market generics expand access but demand strict quality oversight.
- Supply Chain Strategy: Diversification and compliance are critical to mitigate shortages and regulatory risks.
- Regulatory Environment: Ongoing patent expirations present opportunities for new entrants, demanding rigorous in-house quality assurance.
- Future Outlook: Advances in peptide synthesis technology and increasing global demand make the Leuprolide Mesylate market dynamic and opportunities-rich.
FAQs
1. Who are the top global suppliers of Leuprolide Mesylate?
Ferring Pharmaceuticals and AbbVie are the leading global suppliers, with extensive manufacturing and distribution networks across North America, Europe, and Asia.
2. Are there generic options available for Leuprolide Mesylate?
Yes; several generic manufacturers, including Sun Pharma and Sandoz, produce cost-effective versions post-patent expiry, increasing market accessibility.
3. What should buyers consider when sourcing Leuprolide Mesylate?
Ensuring suppliers comply with cGMP standards, verifying product quality, assessing manufacturing capacity, and understanding regulatory approvals are crucial.
4. How does the patent landscape affect supply potential?
Patent expirations have facilitated entry by generic manufacturers, expanding supply sources while reducing costs.
5. What emerging trends could influence future supply of Leuprolide Mesylate?
Technological advances in peptide synthesis, increased focus on manufacturing capacity, and global market expansion are key trends shaping future supply stability.
References
[1] Ferring Pharmaceuticals. Corporate Overview.
[2] AbbVie. Lupron Product Information.
[3] Sun Pharmaceutical Industries. Product Portfolio and Manufacturing Capabilities.
Note: For detailed regulatory compliance and supplier certifications, consult respective manufacturing entities and official regulatory authorities.
More… ↓
